EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

Trends in Pharmacological Sciences

Volumn 37, Issue 11, 2016, Pages 887-903

  Ke, E E ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

ctDNA; EGFR mutation; non small cell lung cancer (NSCLC); third generation EGFR TKIs

Indexed keywords

AFATINIB; AZD 3759; BEVACIZUMAB; CABOZANTINIB; CAPMATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; ICOTINIB; NAQUOTINIB; NAZARTINIB; NIMOTUZUMAB; OLMUTINIB; OSIMERTINIB; PACLITAXEL; PEMETREXED; PLACEBO; ROCILETINIB; SCATTER FACTOR RECEPTOR; TEPOTINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; EGFR GENE; FATIGUE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; MENINGEAL METASTASIS; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; QUALITY OF LIFE; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84992482426     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.09.003     Document Type: Review

References (119)

1. 1 Mendelsohn, J., Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog. Allergy 45 (1988), 47–60.
2. 2 Lynch, T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
3. 3 Paez, J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. 4 Mok, T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
5. 5 Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11 (2010), 121–128.
6. 6 Maemondo, M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362 (2010), 2380–2388.
7. 7 Zhou, C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12 (2011), 735–742.
8. 8 Han, J.Y., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 30 (2012), 1122–1128.
9. 9 Rosell, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
10. 10 Wu, Y.L., et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann. Oncol. 26 (2015), 1883–1889.
11. 11 Yu, H.A., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
12. 12 Sequist, L.V., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011, 75ra26.
13. 13 Li, D., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27 (2008), 4702–4711.
14. 14 Engelman, J.A., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67 (2007), 11924–11932.
15. 15 Miller, V.A., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13 (2012), 528–538.
16. 16 Reckamp, K.L., et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120 (2014), 1145–1154.
17. 17 Cross, D.A., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
18. 18 Walter, A.O., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3 (2013), 1404–1415.
19. 19 Janne, P.A., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
20. 20 Sequist, L.V., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709.
21. 21 Inoue, A., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol. 24 (2013), 54–59.
22. 22 Fukuoka, M., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29 (2011), 2866–2874.
23. 23 Yoshioka, H., et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). J. Clin. Oncol., 32, 2014, abstr8117.
24. 24 Yang, J.J., et al. MINI16.13 A randomized controlled trial of erlotinib versus gefitinib in advanced non-small-cell lung cancer harboring EGFR mutations (CTONG0901). J. Thorac. Oncol., 10, 2015, S321.
25. 25 Shi, Y.K., et al. First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE). J. Clin. Oncol., 34, 2016, abstr9041.
26. 26 Sequist, L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31 (2013), 3327–3334.
27. 27 Wu, Y-L., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15 (2014), 213–222.
28. 28 Yang, J.C-H., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16 (2015), 141–151.
29. 29 Solca, F., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343 (2012), 342–350.
30. 30 Park, K., et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17 (2016), 577–589.
31. 31 Tony, M., et al. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). J. Clin. Oncol., 33, 2015 abstrTPS8123.
32. 32 Shi, Y., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9 (2014), 154–162.
33. 33 Wu, Y.L., et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J. Thorac. Oncol. 2 (2007), 430–439.
34. 34 D'Angelo, S.P., et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J. Clin. Oncol. 29 (2011), 2066–2070.
35. 35 Lee, C.K., et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J. Clin. Oncol. 33 (2015), 1958–1965.
36. 36 Zhang, Y., et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS ONE, 9, 2014, e107161.
37. 37 Kuan, F.C., et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br. J. Cancer 113 (2015), 1519–1528.
38. 38 Karachaliou, N., et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 1 (2015), 149–157.
39. 39 Yang, J.C.H., et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16 (2015), 830–838.
40. 40 Wu, J.Y., et al. Effectiveness of tyrosine kinase inhibitors on ‘uncommon’ epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. 17 (2011), 3812–3821.
41. 41 Asahina, H., et al. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54 (2006), 419–422.
42. 42 Masago, K., et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn. J. Clin. Oncol. 40 (2010), 1105–1109.
43. 43 Watanabe, S., et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J. Thorac. Oncol. 9 (2014), 189–194.
44. 44 Giaccone, G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22 (2004), 777–784.
45. 45 Herbst, R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22 (2004), 785–794.
46. 46 Herbst, R.S., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23 (2005), 5892–5899.
47. 47 Gatzemeier, U., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25 (2007), 1545–1552.
48. 48 Mahaffey, C.M., et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin. Lung Cancer 8 (2007), 548–553.
49. 49 Wu, Y-L., et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 14 (2013), 777–786.
50. 50 Sugawara, S., et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann. Oncol. 26 (2015), 888–894.
51. 51 Cheng, Y., et al. Randomized Phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J. Clin. Oncol. 34 (2016), 3258–3266.
52. 52 van Cruijsen, H., et al. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int. J. Cancer 117 (2005), 883–888.
53. 53 Larsen, A.K., et al. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 131 (2011), 80–90.
54. 54 Seto, T., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15 (2014), 1236–1244.
55. 55 Ichihara, E., et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J. Thorac. Oncol. 10 (2015), 486–491.
56. 56 Matar, P., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10 (2004), 6487–6501.
57. 57 Wheler, J.J., et al. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol. Cancer Ther. 12 (2013), 2167–2175.
58. 58 Janjigian, Y.Y., et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 4 (2014), 1036–1045.
59. 59 Lee, J.Y., et al. A Phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. Clin. Cancer Res. 22 (2016), 2139–2145.
60. 60 Ke, E.E., et al. Emerging paradigms in targeted treatments for Asian patients with NSCLC. Expert Opin. Pharmacother. 16 (2015), 1167–1176.
61. 61 Park, K., et al. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M–positive NSCLC at the recommended phase II dose. J. Thorac. Oncol., 11, 2016, S113.
62. 62 Mitsudomi, T., et al. MINI16.08 AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. J. Thorac. Oncol., 10, 2015, S320.
63. 63 Yang, J., et al. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J. Thorac. Oncol. 11 (2016), S152–S153.
64. 64 Park, K., et al. BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M + NSCLC: Efficacy and safety at the RP2D. J Clin Oncol, 34, 2016, abstr9055.
65. 65 Tan, D.S.W., et al. Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J. Clin. Oncol., 34, 2016, abstr9044.
66. 66 Yu, H.A., et al. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study. J. Clin. Oncol., 34, 2016, abstr9050.
67. 67 Niederst, M.J., et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin. Cancer Res. 21 (2015), 3924–3933.
68. 68 Chabon, J., et al. Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. J. Clin. Oncol., 34, 2016, abstr9000.
69. 69 Song, H-N., et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J. Thorac. Oncol. 11 (2016), e45–e47.
70. 70 Piotrowska, Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5 (2015), 713–722.
71. 71 Kim, T.M., et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 10 (2015), 1736–1744.
72. 72 Oxnard, G.R., et al. ORAL17.07 Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer. J. Thorac. Oncol., 10, 2015, S207.
73. 73 Planchard, D., et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 26 (2015), 2073–2078.
74. 74 Akbay, E.A., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3 (2013), 1355–1363.
75. 75 Creelan, B.C., et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). J. Clin. Oncol., 33, 2015, abstr3047.
76. 76 Ahn, M.J., et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J. Thorac. Oncol., 11, 2016, S115.
77. 77 Li, A., et al. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin. Ther. Targets 19 (2015), 663–674.
78. 78 Reckamp, K.L., et al. Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California Cancer Consortium phase II trial (NCI 9303). J. Clin. Oncol., 32, 2014, abstr8014.
79. 79 Wu, Y.L., et al. Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET + ) non-small cell lung cancer (NSCLC). J. Clin. Oncol., 34, 2016, abstr9020.
80. 80 Soo, R., et al. 469PHighly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met + NSCLC. Ann. Oncol., 26, 2015 ix143.143.
81. 81 Langer, C.J., Mehta, M.P., Current management of brain metastases, with a focus on systemic options. J. Clin. Oncol. 23 (2005), 6207–6219.
82. 82 Matsumoto, S., et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 119 (2006), 1491–1494.
83. 83 Shin, D.Y., et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J. Thorac. Oncol. 9 (2014), 195–199.
84. 84 Kim, J.E., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65 (2009), 351–354.
85. 85 Iuchi, T., et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82 (2013), 282–287.
86. 86 Schuler, M., et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J. Thorac. Oncol. 11 (2016), 380–390.
87. 87 Ahn, M.J., et al. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies. Eur. J. Cancer 51 (2015), S625–S626.
88. 88 Yang, J.C.H., et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. J. Clin. Oncol., 34, 2016, abstr9002.
89. 89 Zeng, Q., et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J. Med. Chem. 58 (2015), 8200–8215.
90. 90 Ahn, M.J., et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). J. Clin. Oncol., 34, 2016, abstr9003.
91. 91 Sundaresan, T.K., et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin. Cancer Res. 22 (2016), 1103–1110.
92. 92 Douillard, J-Y., et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol. 9 (2014), 1345–1353.
93. 93 Kuang, Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Am. Assoc. Cancer Res. 15 (2009), 2630–2636.
94. 94 Kimura, H. et al. (2000) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97, 778–784.
95. 95 Kimura, H., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Am. Assoc. Cancer Res. 12 (2006), 3915–3921.
96. 96 Liu, X., et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J. Clin. Pathol. 66 (2013), 1065–1069.
97. 97 Xu, F., et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco. Targets Ther. 5 (2012), 439–447.
98. 98 Weber, B., et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer 14 (2014), 1–6.
99. 99 Punnoose, E.A., et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase ii clinical trial of pertuzumab and erlotinib. Am. Assoc. Cancer Res. 18 (2012), 2391–2401.
100. 100 Mack, P.C., et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J. Thorac. Oncol. 4 (2009), 1466–1472.
101. 101 Bai, H., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol. 27 (2009), 2653–2659.
102. 102 Huang, Z., et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac. Cancer 3 (2012), 334–340.
103. 103 Jing, C., et al. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac. J. Cancer Prev., 14, 2013, 6619.
104. 104 Zhang, H., et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using Liquidchip technology. J. Mol. Diagn. 15 (2013), 819–826.
105. 105 Yung, T.K.F., et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Am. Assoc. Cancer Res. 15 (2009), 2076–2084.
106. 106 Breitenbuecher, F., et al. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS ONE, 9, 2014, e85350.
107. 107 Wang, W-T., Chen, Y-Q., Circulating miRNAs in cancer: from detection to therapy. J. Hematol. Oncol. 7 (2014), 1–9.
108. 108 Kim, H-R., et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J. Exp. Clin. Cancer Res. 32 (2013), 1–8.
109. 109 Kim, S.T., et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?. Am. J. Clin. Oncol., 36, 2013, 57.
110. 110 Newman, A.M., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20 (2014), 548–554.
111. 111 Thress, K.S., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90 (2015), 509–515.
112. 112 Mok, T., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21 (2015), 3196–3203.
113. 113 Murtaza, M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
114. 114 Taniguchi, K., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17 (2011), 7808–7815.
115. 115 Thress, K.S., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
116. 116 Jia, Y., et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534 (2016), 129–132.
117. 117 Gainor, J.F., Shaw, A.T., Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J. Clin. Oncol. 31 (2013), 3987–3996.
118. 118 Burrell, R.A., et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501 (2013), 338–345.
119. 119 Hata, A.N., et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22 (2016), 262–269.